[Ip-health] Knowledge Ecology International Leaks TPP Text on Intellectual Property

Claire Cassedy clairepcassedy at gmail.com
Tue Aug 4 07:38:25 PDT 2015


Knowledge Ecology International Leaks TPP Text on Intellectual Property

Submitted by Claire Cassedy on 4. August 2015 - 10:29

4 August 2015
CONTACT: Zack Struver
+1 (202) 332-2670
zack.struver at keionline.org

Today, August 4, 2015, Knowledge Ecology International (KEI) released text
from three sections of the 95-page secret negotiating text on the
Intellectual Property Chapter being used in the Trans-Pacific Partnership
Agreement (TPP, sometimes referred to as TPPA) trade negotiations. The
negotiating text is dated May 11, 2015, and reflects the state of the text
right before the Maui rounds of the negotiation, which ended Friday, July
31, 2015.

Released this morning is text from the following sections of the IP Chapter:

-All of Section B on Cooperation. (Pages 8 to 10 of the IP Chapter)
-All of Section E on “Patents / Undisclosed Test or Other Data /
Traditional Knowledge.” (Pages 29 to 53 of the IP Chapter)
-Articles 1 through 11 from Section H on enforcement. (Pages 67 through 89
of the IP Chapter)

We hope to release the remaining sections (A, C, D, F, G, and the rest of
H) later today and Wednesday.

The text will be placed on this web page:

The text released this morning is most relevant to issues related to
pharmaceuticals, especially rules on biologics and new chemicals. Later
today or tomorrow, KEI will release sections of the text relevant to
copyright and trademarks.

KEI will publish a more detailed analysis of the text later. James Love,
Director of Knowledge Ecology International, released the following
statement this morning:

    “KEI is publishing the consolidated text for the TPP IP Chapter from
May 11, 2015, in order to enable the public to understand, analyze, and
influence the rules that have been proposed for intellectual property in
this important trade negotiation. Over 600 corporate advisors already have
access to this text, and this leak, at least temporarily, levels the field
somewhat (there will be a new text coming out of last week’s talks in Maui).

    The May 11, 2015, text includes country positions, and reveals
extensive disagreements among parties, as well as the isolation of the
United States as the country that continues to be the most aggressive
supporter of expanded intellectual property rights for drug companies,
publishers and other companies.

    The proposals contained in the TPP will harm consumers and in some
cases block innovation. In countless ways, the Obama Administration has
sought to expand and extend drug monopolies and raise drug prices. The
astonishing collection of proposals pandering to big drug companies make
more difficult the task of ensuring access to drugs for the treatment of
cancer and other diseases and conditions.

    The widely reported dispute over the number of years of protection for
biologic drug test data is only one of dozens of measures that
significantly expand the power of big drug companies to charge high prices.
Taken together these provisions will take the public down a road of more
and more rationing of medicines, and less and less equality of access. It
could have and still can be different. Rather than focusing on more
intellectual property rights for drug companies, and a death-inducing
spiral of higher prices and access barriers, the trade agreement could seek
new norms to expand the funding of medical R&D as a public good, an area
where the United States has an admirable track record, such as the public
funding of research at the NIH and other federal agencies. Many people
reading the provisions released today will appreciate how misguided and
wrong are the USTR’s values and negotiating objectives.”

  - James Love, Director, KEI, August 4, 2015

For more information and perspectives, we are also attaching the names and
contact information for several persons who can comment on the text
released this morning, including health and consumer group NGOs, academics,
and industry experts.

Health and consumer group NGOs

Knowledge Ecology International
James Love, Director, +1.202.361.3040, james.love at keionline.org
Andrew S. Goldman, Counsel for Policy & Legal Affairs, +1.202.332.2670,
andrew.goldman at keionline.org
Thiru Balasubramaniam, Geneva Representative, thiru at keionline.org , +41 22
791 6727

Public Citizen
Peter Maybarduk, Director, +1.202.588.7755, pmaybarduk at citizen.org
Burcu Kilic, Research Director, +1.202.588.7792, bkilic at citizen.org

Doctors Without Borders/Médecins Sans Frontières
Judit Rius Sanjuan, U.S. Manager & Legal Policy Adviser, Access Campaign,
T: +1.212.655.3762, M: +1.917.331.9077, Judit.Rius at newyork.msf.org


Professor Susan K. Sell
Elliott School of International Affairs
George Washington University
T: (202) 994-4896
susan.sell at gmail.com

Professor Kevin Outterson
Boston University School of Law
mko at bu.edu

Dr. Deborah Gleeson
Department of Public Health
La Trobe University
Melbourne, Australia
T: +61 3 9479 3262
M: +61 423 209029
deborah at gleeson.net

Professor Margot Kaminski
Moritz College of Law
Ohio State University
margot.kaminski at gmail.com

Professor Brook K. Baker
Program on Human Rights and the Global Economy
Northeastern University School of Law
T: (617) 373=3217
M: (617) 259-0760
b.baker at neu.edu

Dr. Ruth Lopert
Department of Public Health
George Washington University
(202) 415-7726
rlopert at gwu.edu

Pharmaceutical and biotechnology industry experts who are familiar with the
TPP IP Chapter

Joseph Damond
Senior Vice President, International Affairs
Biotechnology Industry Organization (BIO)
jDamond at bio.org

Members of USTR’s Industry Trade Advisory Committees (ITAC)

ITAC 15: Industry Trade Advisory Committee on Intellectual Property Rights

Gregg H. Alton, Esq.
Executive Vice President, Corporate and Medical Affairs, Secretary and
Chief Compliance Officer
Gilead Sciences, Inc.

Paul A. Coletti
Associate Patent Counsel
Johnson & Johnson

Erik H. Iverson, Esq.
President, Business and Operations
Infectious Disease Research Institute

Mr. Richard H. Kjeldgaard
Representing Pharmaceutical Research and Manufacturers of America

Jeffrey P. Kushan, Esq.
Sidley Austin
Representing Biotechnology Industry Organization

Jonathan L. Marks, Esq.
Vice President, International Affairs
Generic Pharmaceuticals Association

ITAC 3: Industry Trade Advisory Committee On Chemicals, Pharmaceuticals,
Health/Science Products And Services

Ms. Tiffany McCullen Atwell
Director, International Government Affairs
DuPont Government Marketing and Government Affairs
E.I. du Pont de Nemours and Company

Mr. Harrison C. Cook
Vice President, International Government Affairs
Eli Lilly and Company

Mr. Ralph F. Ives
Executive Vice President, Global Strategy and Analysis
AdvaMed: Advanced Medical Technology Association

Mr. Maurice J. Kerins
Airmed Biotech, Inc.

Douglas T. Nelson, Esq.
Senior Advisor for Trade, Intellectual Property and Strategic Affairs
CropLife America

Mr. Paul A. Neureiter
Executive Director, Government Affairs
Amgen Inc.

Mr. James R. Plante
Founder and Chief Executive Officer
Pathway Genomics

Ms. Lisa M. Schroeter
Global Director, Trade and Investment Policy
The Dow Chemical Company


More information about the Ip-health mailing list